(Q43183447)

15 November 2017

Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes (English)

1 reference

15 November 2017

0 references

1 reference

3

1 reference

15 November 2017

2

Tina Vilsbøll

1 reference

15 November 2017

4

Filip K Knop

1 reference

15 November 2017

Kristine J Hare

1

1 reference

15 November 2017

26 January 2010

1 reference

American Journal of Physiology - Endocrinology and Metabolism

15 November 2017

1 reference

15 November 2017

298

1 reference

15 November 2017

4

1 reference

15 November 2017

E832-7

1 reference

Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose

15 November 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Regulation of alpha-cell function by the beta-cell in isolated human and rat islets deprived of glucose: the "switch-off" hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Glucagon physiology and pathophysiology in the light of new advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Reduced Incretin Effect in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Diminished Immunoreactive Gastric Inhibitory Polypeptide Response to a Meal in Newly Diagnosed Type I (Insulin-Dependent) Diabetics*

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Meal-Stimulated Glucagon Release Is Associated with Postprandial Blood Glucose Level and Does Not Interfere with Glycemic Control in Children and Adolescents with New-Onset Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00700.2009

10.1152/AJPENDO.00700.2009

21 January 2018

Identifiers

DOI

1 reference

15 November 2017

1 reference

PubMed ID

20103744